In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 1, 2012, Pages 65-75

  Gundogdu, Evren ^a   Mangas Sanjuan, V ^b   Gonzalez Alvarez, Isabel ^b   Bermejo, Marival ^b   Karasulu, Ercument ^a  

^a EGE UNIVERSITY   (Turkey)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Caco 2 cell; Dissolution; Fexofenadine; In situ permeability; Sodium dodecyl sulfate

Indexed keywords

DODECYL SULFATE SODIUM; FEXOFENADINE; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; INTESTINE MUCOSA PERMEABILITY; LABORATORY TEST; MALE; MATHEMATICAL ANALYSIS; MONOLAYER CULTURE; NONHUMAN; PH; PROTEIN SECRETION; RAT; SMALL INTESTINE;

ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PERMEABILITY; RATS; RATS, WISTAR; SODIUM DODECYL SULFATE; SOLUBILITY; SURFACE-ACTIVE AGENTS; TERFENADINE;

EID: 84857648060     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0059-4     Document Type: Article

References (34)

1. J Alsenz E Haenel 2003 Development of a 7 day, 96 well Caco-2 permeability assay with high-throughput direct UV compound analysis Pharm Res 20 12 1961 1969 14725360 10.1023/B:PHAM.0000008043.71001.43 1:CAS:528: DC%2BD3sXpvVShsbw%3D (Pubitemid 38005527)
2. EK Anderberg C Nyström P Artursson 1992 Epithelial transport of drugs in cell culture. VII: effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells J Pharm Sci 81 79 87 10.1002/jps.2600810908 (Pubitemid 23006838)
3. EK Anderberg T Lindmark P Artursson 1993 Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route Pharm Res 10 857 864 8321854 10.1023/A:1018909210879 1:CAS:528:DyaK3sXkvVSjtbo%3D (Pubitemid 23167568)
4. P Arora S Sharma S Garg 2002 Permeability issues in nasal drug delivery Drug Discov Today 7 967 975 12546871 10.1016/S1359-6446(02)02452-2 1:CAS:528:DC%2BD38XotVCru7c%3D (Pubitemid 35286901)
5. P Artursson J Karlsson 1991 Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem Biophys Res Commun 175 880 885 1673839 10.1016/0006-291X(91)91647-U 1:CAS:528:DyaK3MXhslOrt7c%3D
6. P Artursson K Palm K Luthman 2001 Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv Drug Deliv Rev 46 1-3 27 43 11259831 10.1016/S0169-409X(00)00128-9 1:CAS:528:DC%2BD3MXitVOhs7s%3D
7. DR Bhangwant PYK Joseph EJ Polli 2002 Effects of nonionic surfactants on membrane transporters in caco-2 cell monolayer Eur J Pharm Sci 16 237 246 10.1016/S0928-0987(02)00055-6
8. E Biganzoli L Cavenaghi R Rossi MC Brunati ML Nolli 1999 Use of caco-2 cell culture model for the characterization of intestinal absorption of antibiotics Il Farmaco 54 9 594 599 10555261 10.1016/S0014-827X(99)00069-5 1:CAS:528:DyaK1MXmslKjtbg%3D (Pubitemid 29462620)
9. A Dahana BT West GL Amidon 2009 Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat Eur J Pharm Sci 36 320 329 10.1016/j.ejps.2008.10.013
10. F Damian N Blaton L Naesens J Balzarini R Kinget P Augustijns G Mooter Van Den 2000 Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14 Eur J Pharm Biopharm 10 311 322 1:CAS:528:DC%2BD3cXjs1Cgs78%3D (Pubitemid 30317467)
11. WW Davis RR Pfeiffer JF Quay 1970 Normal and promoted gastrointestinal absorption of water soluble substances. I. Induced rapidly reversible hyperabsorptive state in the canine fundic stomach pouch J Pharm Sci 59 960 963 5428089 10.1002/jps.2600590708 1:CAS:528:DyaE3cXkslGnsL0%3D
12. Z Degim N Unal D Essiz U Abbasoglu 2004 The effect of various liposome formulations on insulin penetration across caco-2 cell monolayer Life Sci 75 23 2819 2827 15464833 10.1016/j.lfs.2004.05.027 1:CAS:528:DC%2BD2cXotFCmur4%3D (Pubitemid 39349268)
13. MA Deli 2008 Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery Biochim Biophys Acta 1788 892 910 18983815
14. JT Doluisio NF Billups LW Dittert ET Sugita JV Swintosky 1969 Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates J Pharm Sci 58 1196 2000 5394662 10.1002/jps.2600581006 1:CAS:528:DyaE3cXhvVGm
15. AC Foss NA Peppas 2004 Investigation of the cytotoxicity and insulin transport of acrylic-based copolymer protein delivery systems in contact with Caco-2 cultures Eur J Pharm Biopharm 57 3 447 455 15093592 10.1016/j.ejpb.2004. 02.008 1:CAS:528:DC%2BD2cXjt1ShtL4%3D (Pubitemid 38490561)
16. I Gonzalez-Alvarez M Gonzalez-Alvarez D Oltra-Noguera V Merino N Tõkési J Ovádi M Bermejo 2008 Unique pharmacology of KAR-2, a potential anti-cancer agent: absorption modeling and selective mitotic spindle targeting Eur J Pharm Sci 36 1 9 11
17. I González-Alvarez C Fernández-Teruel TM Garrigues VG Casabo A Ruiz-García M Bermejo 2005 Kinetic modeling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM Xenobiotica 35 12 1067 1088 16418062 10.1080/00498250500354469 (Pubitemid 43163247)
18. I González-Alvarez C Fernández-Teruel VG Casabó-Alós TM Garrigues JE Polli A Ruiz-García M Bermejo 2007 In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results Biopharm Drug Dispos 28 5 229 239 17410527 10.1002/bdd.548 (Pubitemid 47180172)
19. Guidance for Industry (2000) Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, U.S. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER)
20. ED Hugger BL Novak PS Burton KL Audus RT Borchardt 2002 A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro J Pharm Sci 91 9 1991 2002 12210046 10.1002/jps.10176 1:CAS:528:DC%2BD38XmsVSgs7Y%3D (Pubitemid 36254935)
21. A Jain Y Ran SH Yalkowsky 2004 Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note AAPS PharmSciTech 5 3 45 10.1208/pt050345
22. C Leuner J Dressman 2000 Improving drug solubility for oral delivery using solid dispersions Eur J Pharm Biopharm 50 47 60 10840192 10.1016/S0939-6411(00)00076-X 1:CAS:528:DC%2BD3cXjslyju7c%3D (Pubitemid 30326688)
23. C Lippert J Ling PL Brown 1995 Mass balance and pharmacokinetics of fexofenadine HCl in healthy, male volunteers Pharm Res 12 390
24. C MacLean U Moenning A Reichel G Fricker 2010 Regional absorption of fexofenadine in rat intestine Eur J Pharm Sci 41 5 670 674 20869437 10.1016/j.ejps.2010.09.007 1:CAS:528:DC%2BC3cXhsValtbbM
25. L Olse NC Ingvast-Larsson P Larsson H Brostro MU Bondesson M SundqvIst LH Tja 2006 Fexofenadine in horses: pharmacokinetics. Pharmacodynamics and effect of ivermectin pretreatment J Vet Pharmacol Ther 29 129 135 10.1111/j.1365-2885. 2006.00724.x (Pubitemid 43332394)
26. N Petri C Tannergren D Rungstad H Lennernäs 2004 Transport characteristics of fexofenadine in the Caco-2 cell model Pharma Res 21 8 1398 1404 10.1023/B:PHAM.0000036913.90332.b1 1:CAS:528:DC%2BD2cXmtlGnurk%3D (Pubitemid 39149654)
27. P Shah V Jogani T Bagchi A Misra 2006 Role of Caco-2 cell monolayers in prediction of intestinal drug absorption Biotechnol Prog 22 186 198 16454510 10.1021/bp050208u 1:CAS:528:DC%2BD2MXht1Gms7%2FJ (Pubitemid 43221545)
28. M Shimizu T Uno K Sugawara T Tateishi 2006 Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein Br J Clin Pharmacol 61 5 538 544 16669847 10.1111/j.1365-2125.2006.02613.x 1:CAS:528:DC%2BD28XlvFSrtLs%3D
29. GL Susman J Mason D Compton J Stewart N Ricard 1999 The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis J Allergy Clin Immunol 104 1 100 106 10.1016/S0091-6749(99)70120-X (Pubitemid 29364487)
30. MH Terrien F Rahm JM Fellrath F Spertini 1999 Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen J Allergy Clin Immunol 103 6 1025 1030 10359881 10.1016/S0091-6749(99)70174-0 1:CAS:528:DyaK1MXktlSnuro%3D (Pubitemid 29343065)
31. S Turker E Onur Y Ozer 2004 Nasal route and drug delivery systems Pharm World Sci 26 137 142 15230360 10.1023/B:PHAR.0000026823.82950.ff (Pubitemid 39012580)
32. IM Twiss R De Water J Hartigh R Sparidans W Ramp-Koopmanschap H Brill M Wjideveld P Vermeij 1994 Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial cells and its epithelial transport J Pharm Sci 83 5 699 703 8071824 10.1002/jps.2600830521 1:CAS:528:DyaK2cXivV2rsLc%3D (Pubitemid 24219823)
33. A Weissenboeck E Bogner M Wirth F Gabor 2004 Binding and uptake of wheat germ agglutinin-grafted PLGA nanospheres by caco-2 monolayers Pharm Res 21 10 1917 1923 15553240 10.1023/B:PHAM.0000045247.09724.26 1:CAS:528: DC%2BD2cXos1Wqtrs%3D (Pubitemid 39390104)
34. S Yamashita T Furubayashi M Kataoka T Sakane H Sezaki H Tokuda 2000 Optimized conditions for prediction of intestinal permeability using Caco-2 cells Eur J Pharm Sci 10 3 195 204 10767597 10.1016/S0928-0987(00)00076-2 1:CAS:528:DC%2BD3cXitlOksL8%3D (Pubitemid 30190095)